SystImmune Advances SI-B037 Into Phase 1/1b Trial
Redmond, Washington, U.S., September 22, 2026 SystImmune, Inc. has announced that the U.S. Food and Drug Administration (FDA) has...
SI-B037
Advertisement
Advertisement
Advertisement
Redmond, Washington, U.S., September 22, 2026 SystImmune, Inc. has announced that the U.S. Food and Drug Administration (FDA) has...
Advertisement